Join us on Thursday, September 21^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess the anticipated benefits, risks and long-term outcomes associated with adjuvant and neoadjuvant therapy for localized non-small cell lung cancer (NSCLC), and consider this information when counseling patients regarding therapeutic recommendations.
• Analyze the biological basis for the investigation of immune checkpoint inhibitors for patients with localized NSCLC, and evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibodies as neoadjuvant and adjuvant therapy.
• Evaluate published clinical research data with EGFR-directed therapy as adjuvant treatment for localized NSCLC with an EGFR mutation, and identify patients for whom this novel approach would be warranted.
• Recognize adverse events associated with anti-PD-1/PD-L1 antibodies and EGFR-directed therapy for patients with localized NSCLC, and understand the supportive strategies available to minimize and manage these toxicities.
• Recall the design of ongoing clinical trials evaluating novel investigational strategies for localized NSCLC, and appropriately counsel patients about availability and participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Chaft  — Consulting Agreements: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Flame Biosciences, Genentech, a member of the Roche Group, Guardant Health, Lilly, Merck, Regeneron Pharmaceuticals Inc. Dr Heymach — Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol Myers Squibb, Catalyst Pharmaceuticals, Chugai Pharmaceutical Co Ltd, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Hengrui Therapeutics Inc, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Nexus Health Systems, Pneuma Respiratory, RefleXion, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc. 

SURVEY PARTICIPANTS — Mark Awad, MD, PhD — Information pending. Patrick Forde, MD — No relevant conflicts of interest to disclose. Ramaswamy Govindan, MD — No relevant conflicts of interest to disclose. Heather Wakelee, MD, FASCO — Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Genentech, a member of the Roche Group (uncompensated), Merck (uncompensated), Mirati Therapeutics Inc; Contracted Research: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Clovis Oncology, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Merck, Novartis, Seagen Inc, Xcovery; Nonrelevant Financial Relationship: ECOG-ACRIN (executive committee).

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.